Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  ImmunoGen, Inc.    IMGN   US45253H1014

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Sales16,435,559,989,587,472,1
Operating income (EBITDA)--68,4-66,9-59,0-78,9-78,1
Operating profit (EBIT)-73,3-73,0-71,5-56,5-92,8-93,5
Pre-Tax Profit (EBT)-73,3-72,8----
Net income-73,3-72,8-71,4-60,8-117-121
EPS ( $)-0,95-0,87-0,83-0,71-1,39-1,38
Dividend per Share ( $)------
Yield------
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Debt------
Finance-19514284,648,168,4
Operating income (EBITDA)--68,4-66,9-59,0-78,9-78,1
Leverage
(Debt/EBITDA)
------
Capital Expenditure2,903,778,187,917,827,83
Book Value Per Share (BVPS)-1,44 $0,88 $0,49 $-0,23 $
Cash Flow per Share--0,72 $-0,63 $-0,71 $-0,88 $-1,16 $
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Balance Sheet Analysis
Assessed data source :
© 2015 Thomson Reuters
Advertisement
Financial Ratios

Size 2015e 2016e
Capitalization 1 501 M$ -
Entreprise Value (EV) 1 417 M$ 1 453 M$
Valuation 2015e 2016e
PER (Price / EPS)
Capitalization / Revenue 16,8x 17,2x
EV / Revenue 15,8x 16,6x
EV / EBITDA -24,0x -18,4x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 35,6x -
Profitability 2015e 2016e
Operating Margin (EBIT / Sales) -63,1% -106%
operating Leverage (Delta EBIT / Delta Sales) 0,43x -27,4x
Net Margin (Net Profit / Revenue) -67,9% -134%
ROA (Net Profit / Asset) -27,5% -39,2%
ROE (Net Profit / Equities) -72,0% -149%
Rate of Dividend - -
Balance Sheet Analysis 2015e 2016e
CAPEX / Sales   8,84% 8,94%
Cash Flow / Sales (Taux d'autofinancement) -68,4% -86,8%
Capital Intensity (Assets / Sales) 2,47x 3,43x
Financial Leverage (Net Debt / EBITDA) 1,43x 0,61x
EPS & Dividend